Physician profile
Marcus Trybula
NPI 1487114989
$3,000.80
in general payments reported to CMS, 2019-2025
35 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $459 · 2023: $731 · 2024: $1,011 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.49 |
| Education | $387.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $352.61 | 2022-2024 | Tukysa, Adcetris |
| Incyte Corporation | $264.70 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Merck Sharp & Dohme LLC | $231.88 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $196.47 | 2024 | |
| Astellas Pharma US INC | $188.38 | 2023-2024 | Xospata, Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $181.60 | 2023-2025 | Fruzaqla, Iclusig |
| Pfizer INC. | $162.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $156.30 | 2023-2025 | Lynparza, Imfinzi, Tagrisso |
| Celgene Corporation | $113.05 | 2023-2025 | Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $102.26 | 2024-2025 | Enhertu |
| Genzyme Corporation | $94.27 | 2022-2025 | |
| Blueprint Medicines Corporation | $92.87 | 2024-2025 | Ayvakit |
| Beone Medicines USA, INC. | $86.49 | 2025 | Brukinsa, Tevimbra |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Eisai INC. | $78.55 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $67.02 | 2022-2023 | Lumakras, Blincyto |
| Alexion Pharmaceuticals, INC. | $60.59 | 2022-2025 | Ultomiris |
| Abbvie INC. | $52.78 | 2024 | |
| Sobi, INC | $42.44 | 2024-2025 | |
| Gilead Sciences, INC. | $41.23 | 2023-2024 | Trodelvy |
| Jazz Pharmaceuticals INC. | $39.47 | 2023-2024 | Zepzelca |
| Rigel Pharmaceuticals, INC. | $39.06 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Array Biopharma INC | $32.70 | 2022 | |
| Lilly USA, LLC | $26.60 | 2025 | Verzenio, Jaypirca |
| Agios Pharmaceuticals, INC. | $24.67 | 2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $23.06 | 2025 | |
| Stemline Therapeutics INC. | $22.96 | 2025 | Elzonris |
| Genentech USA, INC. | $22.60 | 2025 | Itovebi |
| E.R. Squibb & Sons, L.L.C. | $21.24 | 2023 | Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $18.77 | 2022 | |
| Beigene USA, INC. | $18.31 | 2023 | Brukinsa |
| Genmab U.S., INC. | $18.13 | 2023 | Epkinly |
| Janssen Biotech, INC. | $17.99 | 2025 | Rybrevant |
| Springworks Therapeutics, INC. | $13.79 | 2024 | Ogsiveo |
| Novocure INC. | $13.55 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Trybula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.